JPMorgan Weighs in on Eli Lilly's (LLY) Upcoming Donanemab Data
Tweet Send to a Friend
JPMorgan analyst Chris Schott reiterated an Overweight rating and $240.00 price target on Eli Lilly (NYSE: LLY) as investors approach ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


